scholarly article | Q13442814 |
P356 | DOI | 10.1179/1528433614Z.0000000006 |
P698 | PubMed publication ID | 25777188 |
P50 | author | Jaime H Vera | Q42237581 |
Borja Mora Peris | Q84299648 | ||
Marta Boffito | Q95614617 | ||
P2093 | author name string | David Back | |
Tristan Barber | |||
Alan Winston | |||
Akil Jackson | |||
Laura Dickinson | |||
Laura Else | |||
P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
HIV infection and older Americans: the public health perspective | Q26858824 | ||
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. | Q35608904 | ||
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals | Q36675900 | ||
Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population | Q37203653 | ||
Status of computerized cognitive testing in aging: a systematic review. | Q37326855 | ||
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity | Q37378238 | ||
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor | Q37826300 | ||
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients | Q43102292 | ||
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study | Q43867180 | ||
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics | Q44249118 | ||
Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection | Q44400672 | ||
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study | Q44518022 | ||
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme | Q45402590 | ||
HIV transmission and high rates of late diagnoses among adults aged 50 years and over | Q45549222 | ||
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. | Q51486190 | ||
Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. | Q51595257 | ||
The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. | Q51986377 | ||
Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. | Q52012550 | ||
Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population | Q57990925 | ||
P433 | issue | 1 | |
P921 | main subject | pharmacokinetics | Q323936 |
P304 | page(s) | 39-42 | |
P577 | publication date | 2015-01-14 | |
P1433 | published in | HIV Clinical Trials | Q15756361 |
P1476 | title | The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. | |
P478 | volume | 16 |
Q57180790 | British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 |
Q40360498 | Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection |
Q47569821 | Precision medicine for HIV: where are we? |
Search more.